Skip to main content
Valbiotis logo

Valbiotis — Investor Relations & Filings

Ticker · ALVAL ISIN · FR0013254851 LEI · 969500VP4JBJCF0MOP60 PA Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country FR France
Listing PA ALVAL

About Valbiotis

https://www.valbiotis.com/en/

Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.

Recent filings

Filing Released Lang Actions
VALBIOTIS SA: Valbiotis continues its expansion in Asia
Regulatory Filings Classification · 30% confidence The document is a corporate press release announcing the creation of a new subsidiary in Singapore via a joint venture, outlining business expansion and commercial launch plans. It contains no financial statements, no regulatory certification of a report, no share issuance or repurchase details, no dividend notice, no earnings figures, and no governance or M&A bid. It is a general business update and thus falls under the fallback category for miscellaneous regulatory announcements.
2026-05-11 English
VALBIOTIS SA: Valbiotis poursuit son déploiement en Asie
Regulatory Filings Classification · 75% confidence The document is a press release (“communiqué de presse”) announcing the creation of a new subsidiary in Singapore by a Chinese joint venture and outlining the company’s business expansion in Asia. It contains no financial results, no specific report attachments, no regulatory certifications, no share transactions, and no invitation to vote or vote results. It is not an investor presentation, earnings release, management report, or interim/annual report. Therefore, it fits best into the fallback category for general corporate/regulatory announcements. Classification: Regulatory Filings (RNS).
2026-05-11 French
VALBIOTIS SA: Valbiotis continues its expansion in Asia
Regulatory Filings Classification · 90% confidence The document is a French Regulatory News press release (inside information) announcing the business expansion of Valbiotis in Asia. It contains no financial statements, management changes, capital transactions, or results. It is a general corporate announcement distributed via a regulatory news service. It therefore falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-05-11 English
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Major Shareholding Notification Classification · 95% confidence The document is a monthly information update regarding the total number of voting rights and shares composing the share capital of Valbiotis, as per Article 223-16 of the General Regulation of the Autorité des Marchés Financiers. It includes specific data on the number of shares and voting rights as of 30/04/2026 and references legal obligations for shareholders crossing ownership thresholds. The document is short (3108 characters) and does not contain financial statements or detailed financial performance data. It is a regulatory disclosure about shareholding and voting rights, not a full report or announcement of a meeting or vote results. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related voting rights disclosures.
2026-05-07 French
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Major Shareholding Notification Classification · 95% confidence The document is a regulatory announcement dated 7 May 2026 from Valbiotis SA providing monthly information about the total number of voting rights and shares composing the company's share capital. It references Article 223-16 of the French AMF General Regulation, which governs disclosure of voting rights and share capital. The content is factual, concise, and focused on share capital and voting rights data as of 30 April 2026. There is no financial performance data, no management discussion, no earnings information, no meeting materials, or other report content. The document is a regulatory disclosure about share capital and voting rights, which fits the category of Major Shareholding Notification (MRQ) or related capital structure disclosures. Given the focus on voting rights and share capital numbers, and the mention of thresholds for shareholding notifications, the best fit is Major Shareholding Notification (MRQ). The document length is about 5,295 characters, which is consistent with a detailed regulatory announcement but not a full report. Therefore, the classification is MRQ with high confidence.
2026-05-07 French
VALBIOTIS SA: Valbiotis expands its e-commerce to Belgium and Luxembourg
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing the expansion of Valbiotis’ e-commerce delivery to Belgium and Luxembourg. It does not contain financial results, regulatory filings, board changes, dividends, or other report types. It is a general announcement that does not fit any specific category, so it defaults to a Regulatory Filings (RNS) fallback.
2026-04-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.